Da Vinci Laboratory Solutions accelerates growth through acquisition of JSB
Amsterdam, April 10, 2024 –Our portfolio company Da Vinci Laboratory Solutions (Da Vinci) is acquiring industry peer JSB. Da Vinci and JSB are two well-established companies in the international analytical chemistry market with a focus on chromatography. With the unification of Da Vinci and JSB, Da Vinci strengthens its position as a leading player in the field of knowledge-intensive total solutions in chromatography in the Benelux and beyond.
Developer of specialized chromatography solutions
Da Vinci and JSB operate as suppliers of analytical systems to laboratories, specifically based on chromatography and mass spectrometry. Within these niche markets, Da Vinci and JSB are known as knowledge-intensive companies, delivering added value based on systems from the publicly traded American company Agilent Technologies. Specifically, Da Vinci and JSB integrate chromatography systems with in-house developed and third-party systems to provide a customized total solution to the customer. Around these custom-made chromatography systems, both companies provide consumables as well as technical maintenance and installation services.
Joining forces
The chromatography market is subject to growing customer demand for increasingly complex and sensitive measurements. This desire from customers requires continuous technological development and product knowledge from companies such as Da Vinci and JSB. The unification of Da Vinci and JSB brings together two complementary product and service portfolios, enabling the combination to meet this customer demand even better. The acquisition also strengthens Da Vinci’s international footprint with an office in the United Kingdom, in addition to already existing international offices in India, China and Singapore.
In his new role, Sander Affourtit, COO of JSB, will become the operational director of the merged value-added partners of Agilent: “This increase in scale provides synergy for both parties knowledge and expertise can be shared, thus generating additional strength. Since the product package is complementary, more high-end chromatographic solutions will also become available through the combination.”
Martijn van Raalte CEO Da Vinci, “This merger enables us to create synergies, offer more innovative solutions, provide broader services and better meet the specific needs of our customers in various sectors.”
Philip Wilms, Investment Director Holland Capital, “The acquisition of JSB is an important step in the inorganic growth trajectory of Da Vinci. The market in which both companies operate is international, and having combined the two leading Benelux players we now aim to also expand this acquisition path internationally.”
About JSB
Since 2002 JSB has been active on the Benelux market as a full knowledge partner in chromatographic and mass spectrometric solutions. JSB is one of Agilent’s larger partners in the Netherlands and adds value on the Agilent systems by integrating these systems with complementary modules (e.g., sample preparation and detection equipment) to provide a customized solution for customers. JSB has 19 employees and has offices in Lelystad, Eindhoven and in the UK.
About Da Vinci Laboratory Solutions
Da Vinci Laboratory Solutions was founded as a service provider within the laboratory industry in 2000. Since then Da Vinci has grown to become the versatile partner for laboratories by offering chromatographic solutions for all analytical challenges from sample preparation, analysis, reporting, data management, consumables and technical support. Like JSB, Da Vinci is a value-added reseller of Agilent Technology. Da Vinci has offices in Rotterdam (HQ), Geleen, India, China and Singapore. The company has 50 employees and offers an extensive application and test laboratory, training room and R&D facilities. Da Vinci’s mission is to increase laboratory efficiency with its chromatographic solutions.
About Holland Capital
Holland Capital has been investing responsibly and successfully in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and pursues an open, sustainable and professional relationship with the management teams of the companies in which it invests, with the common goal of achieving growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams it concentrates on the Healthcare, Technology and the recently added focus area Agrifood-Tech. It knows the dynamics and opportunities in these sectors and has a broad network. Holland Capital has been involved in Da Vinci as a shareholder since October 2022. She actively supports the organization in both the operational and strategic development of the company.
Gullimex trekt investeerder Holland Capital aan voor verdere groei
Investeringsmaatschappij Holland Capital investeert in Gullimex, een sterke speler op het gebied van meet-, kwaliteit- en controleoplossingen in de food en medical sector. De investering van Holland Capital biedt Gullimex de mogelijkheid de gestelde groeiambities te realiseren.
Our portfolio company Sirius Medical is partnering with Mammotome
Our portfolio company Sirius Medical, the innovator of Surgical Marker Navigation and Mammotome, a globally recognized leader in breast care, are proud to announce an exclusive distribution agreement for the United States and Germany.
Ons portfoliobedrijf Sirius Medical en Mammotome gaan samenwerking aan
Ons portfoliobedrijf Sirius Medical, pionier op het gebied van Surgical Marker Navigation, en Mammotome, een wereldwijd erkende leider in borstkankerzorg, zijn trots om een exclusieve distributieovereenkomst voor de Verenigde Staten en Duitsland aan te kondigen.
Our portfolio company Sirius Medical secures growth funding from new and existing investors
Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day.
Sirius Medical haalt groeifinanciering op bij nieuwe en bestaande investeerders
Ons portfolio bedrijf Sirius Medical, een toonaangevend medisch-technologiebedrijf en marktleider in onco-chirurgische marker-navigatie, heeft een financiering van € 10 miljoen euro opgehaald op Wereldkankerdag.
Beyonder is de nieuwe naam van House of Clouds
House of Clouds heeft een belangrijke stap gezet in haar groeiambities en gaat vanaf vandaag verder onder de naam Beyonder. Tijdens een feestelijke bijeenkomst in het Eindhovense Natlab onthulde CEO Sander Dekker de nieuwe naam en merkidentiteit, samen met alle collega’s.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl


